

**REMARKS**

The application has been examined for restriction purposes only. The Examiner alleges that pending claims 1 to 73 are directed to four independent and patentably distinct inventions, as follows:

- |           |   |  |
|-----------|---|--|
| Group I   | : | Claims 1 through 68, directed to a context-activated protide                                     |
| Group II  | : | Claim 69, directed to a method of treating vascular injury;                                      |
| Group III | : | Claim 70, directed to a method of treating a neoplastic condition                                |
| Group IV  | : | Claim 71, directed to a method of treating microbial infection;                                  |
| Group V   | : | Claim 72, directed to a method of treating a condition associated with decreased cell death; and |
| Group VI  | : | Claim 73, directed to a method of treating an inflammatory condition.                            |

The Examiner requests that one of the groups of claims be elected for examination. Applicants, with traverse, elect the claims of Group I, claims 1-68, for examination.

The Office Action also asserts that claims 1-68 are directed to patentably distinct species. In accordance with this election of species requirement. Applicants select the following species:

Sequence: SEQ ID NO: 1 as in Claim 1, 2, 12, 34 (each in part), 3-11,13-17, 35, 38, 46, 49-58.

Activator site: Shown by arrow in Figure 12, sequence PT-1; as in Claim 1, 2, 12, 34 (each in part), 3-11,13-17, 35, 38, 46, 49-58.

Activator: protease (staphylococcal V8 protease)

Effector sites: chemokine-like peptide (IL-8 domain), as indicated in Figure 12, sequence PT-1 (all claims)

antimicrobial peptide (RP-1), as indicated in Figure 12, sequence PT-1 (all claims)

Biological function: RP-1: antimicrobial (all claims)

IL-8: recruitment and stimulation of neutrophils in response to infection (all claims)

**CONCLUSION**

To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

/Victor Behar/

Victor Behar  
Registration No. 60,691

4370 La Jolla Village Drive, Suite 700  
San Diego, CA 92122  
Phone: 858.535.9001 VB:cjh  
Facsimile: 858.597.1585  
**Date: September 12, 2008**

**Please recognize our Customer No. 41552  
as our correspondence address.**